14 Patients with larger bodies are affected by weight-based marginalization driven by commercial and societal forces
However, the best option depends on your health, eligibility, and cost, so a doctors guidance is important
If youve been searching for solutions, you might be surprised to learn that GLP-1 agonistsmedications originally designed for diabetes and weight managementcould be a game-changer for perimenopausal symptoms
However, there are some differences in the way both drugs work or are used
With the rapid emergence of antifungal resistance and an inadequate pipeline of new therapies, novel treatment strategies are now urgently required
India: Novo Nordisks patent expired March 20, 2026